Clinical Trial Detail

NCT ID NCT03586024
Title Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

mature T-cell and NK-cell lymphoma

diffuse large B-cell lymphoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.